News | Breast Imaging | December 02, 2020

Hologic Receives FDA Clearance for Genius AI Detection

Studies show new deep-learning algorithm helps radiologists detect breast cancers in their early stages when used with the Genius 3D Mammography exam

Studies show new deep-learning algorithm helps radiologists detect breast cancers in their early stages when used with the Genius 3D Mammography exam

December 2, 2020 — Hologic, Inc., an innovative medical technology company primarily focused on improving women’s health, announced U.S. Food and Drug Administration (FDA) clearance and commercial availability of the Company’s Genius AI Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.

The new technology represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius 3D Mammography exam. The new technology highlights areas with subtle potential cancers that can be difficult to detect for further examination by the radiologist, and is designed to provide higher sensitivity and a false-positive rate much lower than Hologic’s previous generation CAD products.

“As the latest breakthrough in breast cancer screening, Genius AI Detection reinforces Hologic’s commitment to improving cancer detection, optimizing workflow and enhancing the patient experience across every step of the breast health care continuum,” said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. “Not only did studies show that Genius AI Detection aids in image interpretation by highlighting suspicious, and often subtle, areas of interest, it also provides the radiologist the opportunity to prioritize the most concerning patient cases. This is a real game changer as it has the potential to shorten the cycle between screening and diagnostic follow-up, and ultimately improve patient outcomes.”

The new software delivers key metrics at the time of image acquisition to help radiologists categorize and prioritize cases by complexity and expected read time in order to optimize workflow and expedite patient care. It is the only deep learning product on the market that runs on the acquisition workstation of the mammography system without the need for a separate server, providing a simple, convenient and secure environment.

The Genius AI Detection software is the only 3D CAD solution that supports Hologic’s latest innovations in tomosynthesis imaging, Clarity HD and 3DQuorum imaging technology, in addition to standard-resolution tomosynthesis. To learn more, visit https://www.hologic.com/GeniusAI-Detection.

The Genius 3D Mammography exam is acquired on the Hologic 3D Mammography system and consists of a 2D and 3D image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D image set. The Genius exam is only available on the Hologic 3D Mammography system.

For more information: www.hologic.com

Related Content

For years telehealth has danced at the edges of healthcare
Feature | Teleradiology | January 21, 2021 | By Jef Williams
All indications point to 2021 being the year of the return path of this boomerang event that sent us all in a differe
Steinberg Diagnostic Medical Imaging headquarters.

Steinberg Diagnostic Medical Imaging headquarters.

Sponsored Content | Case Study | Contrast Media Injectors | January 21, 2021
Steinberg Diagnostic Medical Imaging (SDMI) was founded 30 years a
Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
An interview with Eric Liederman, M.D., MPH, Director of Medical Informatics for The Permanente Medical Group, in Kaiser Permanente’s Northern California Region, on the explosion of telemedicine in the COVID-19 era

Getty Images

Feature | Radiology Business | January 20, 2021 | By Melinda Taschetta-Millane
Vendor neutral archives enable a single, central location to store large volumes of radiology data, but now need to be able to house data from dozens of other departments with a wide array of data formats. This article originally ran as an introduction to the Vendor Neutral Archives comparison chart.
Feature | Vendor Neutral Archive (VNA) | January 20, 2021 | By Dave Fornell
Most radiologists and clinicians are not trained as...
According to a new research report1 on the contrast media injectors published by MarketsandMarkets, the market was estimated to be $1.3 billion in 2020 and projected to reach $1.9 billion by 2025, at a compound annual growth rate (CAGR) of 7.4 percent over 2020-2025.

The ulrich CTmotion

Feature | Contrast Media Injectors | January 20, 2021 | By Melinda Taschetta-Millane
According to a new...
Previously approved by FDA in the USA, MyLab X8 expands the reach of the MyLab Ultrasound Product Line with a fully featured premium imaging solution, integrating the latest technologies and delivering superior image quality without compromising workflow or efficiency.
News | Ultrasound Imaging | January 20, 2021
January 20, 2021 — Esaote North America announces that the...